Sarepta Therapeutics Inc (SRPT)

26.78
NASDAQ : Health Care
Prev Close 25.76
Day Low/High 25.75 / 27.13
52 Wk Low/High 8.00 / 41.97
Avg Volume 3.53M
Exchange NASDAQ
Shares Outstanding 47.90M
Market Cap 1.23B
EPS -5.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta

Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Sarepta Therapeutics (SRPT) Stock Falls, Janney: 'Stay on the Sidelines'

Sarepta Therapeutics (SRPT) Stock Falls, Janney: 'Stay on the Sidelines'

Following speculation that Sarepta Therapeutics's (SRPT) muscular dystrophy therapy is struggling to gain approval, Janney highlighted downside risk to the stock.

Sarepta (SRPT) Stock Advances on Phase III Trial Recruitment

Sarepta (SRPT) Stock Advances on Phase III Trial Recruitment

Sarepta (SRPT) stock is advancing in afternoon trading after a government website indicated the biopharmaceutical company is recruiting patients in its Phase III trials to treat Duchenne muscular dystrophy.

Who Needs a Revenue Stream?

Though highly speculative, Sarepta Therapeutics could be a short-term play.

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

European regulators have delayed PTC Therapeutics' request for permanent approval of its Duchenne muscular dystrophy drug Translarna.

Sarepta Therapeutics (SRPT) Stock Falls on Q2 Earnings Loss

Sarepta Therapeutics (SRPT) Stock Falls on Q2 Earnings Loss

Sarepta Therapeutics (SRPT) met analysts’ 2016 second quarter earnings expectations, recording a net loss for the quarter.

Sarepta Therapeutics Announces Second Quarter 2016 Financial Results And Recent Corporate Developments

Sarepta Therapeutics Announces Second Quarter 2016 Financial Results And Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three and six months ended June 30, 2016, and provided an update of recent corporate...

Duchenne Drug Developer (Not Sarepta) Hit With Lengthy FDA Delay

Duchenne Drug Developer (Not Sarepta) Hit With Lengthy FDA Delay

Santhera's timetable for approval in the U.S. of its Duchenne drug Raxone is pushed back to 2020 after the FDA said a second, successful phase III study will be required.

SRPT: Insiders vs. Shorts

SRPT: Insiders vs. Shorts

The most recent short interest data was recently released for the 06/30/2016 settlement date, and Sarepta Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 6.19 "days to cover" versus the median component at 4.51. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Today's Dead Cat Bounce Stock: Sarepta Therapeutics (SRPT)

Today's Dead Cat Bounce Stock: Sarepta Therapeutics (SRPT)

Trade-Ideas LLC identified Sarepta Therapeutics (SRPT) as a "dead cat bounce" (down big yesterday but up big today) candidate

SRPT August 26th Options Begin Trading

SRPT August 26th Options Begin Trading

Investors in Sarepta Therapeutics Inc saw new options begin trading today, for the August 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SRPT options chain for the new August 26th contracts and identified one put and one call contract of particular interest.

Sarepta Stock Price Lifted by 'No Bad News Is Good News' Argument

Sarepta Stock Price Lifted by 'No Bad News Is Good News' Argument

Every day without bad news from Sarepta boosts odds Western blots performed on patients' muscle samples came back with enough eteplirsen dystrophin production to warrant sending the data to FDA.

Sarepta Therapeutics (SRPT) Is Today's Perilous Reversal Stock

Sarepta Therapeutics (SRPT) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Sarepta Therapeutics (SRPT) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Sarepta Therapeutics (SRPT) Is Today's Post-Market Leader Stock

Trade-Ideas: Sarepta Therapeutics (SRPT) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Sarepta Therapeutics (SRPT) as a post-market leader candidate

'Mad Money' Lightning Round: You Should Be Buying Visa

'Mad Money' Lightning Round: You Should Be Buying Visa

Cramer says Wynn is fantastic but he's avoiding Valeant.

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

When short-sellers get caught leaning the wrong way, that's a recipe for explosive moves to the upside, Cramer says.

Sarepta Push for Duchenne Drug Approval Helped by Clinical Trial Changes

Sarepta Push for Duchenne Drug Approval Helped by Clinical Trial Changes

Digging into the latest bull-bear debate over Sarepta and its Duchenne drug eteplirsen.

August 5th Options Now Available For Sarepta Therapeutics (SRPT)

August 5th Options Now Available For Sarepta Therapeutics (SRPT)

Investors in Sarepta Therapeutics Inc saw new options begin trading today, for the August 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SRPT options chain for the new August 5th contracts and identified one put and one call contract of particular interest.

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.

First Week of SRPT February 2017 Options Trading

First Week of SRPT February 2017 Options Trading

Investors in Sarepta Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Sarepta (SRPT) Stock Spikes on $37.5 Million Stock Offering

Sarepta (SRPT) Stock Spikes on $37.5 Million Stock Offering

Sarepta (SRPT) stock is rising Thursday afternoon after the biopharmaceutical company said it would raise approximately $37.5 million in a stock offering.

Sarepta Therapeutics Announces Common Stock Offering

Sarepta Therapeutics Announces Common Stock Offering

Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W.

Sarepta Therapeutics Announces Proposed Offering

Sarepta Therapeutics Announces Proposed Offering

Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W.

Today's Perilous Reversal Stock: Sarepta Therapeutics (SRPT)

Today's Perilous Reversal Stock: Sarepta Therapeutics (SRPT)

Trade-Ideas LLC identified Sarepta Therapeutics (SRPT) as a "perilous reversal" (up big yesterday but down big today) candidate

Sarepta, FDA Compromise on Plan to Secure Duchenne Drug Approval

Sarepta, FDA Compromise on Plan to Secure Duchenne Drug Approval

Under the new plan, Sarepta will submit to FDA additional clinical data aimed at confirming eteplirsen's ability to produce dystrophin, the muscle-lubricating protein that is missing in patients with DMD.

Trade-Ideas: Sarepta Therapeutics (SRPT) Is Today's Post-Market Leader Stock

Trade-Ideas: Sarepta Therapeutics (SRPT) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Sarepta Therapeutics (SRPT) as a post-market leader candidate

Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision On Eteplirsen NDA

Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision On Eteplirsen NDA

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.